At a Glance
Albert David Ltd (ADL), a nearly century-old pharma player, just posted a Q1 FY26 disaster: sales at ₹70.6 crore (-21% YoY) and PAT at ₹7.9 crore (-58% YoY). With operating margins crashing to -15% and a P/E north of 79, the stock at ₹878 seems to be priced for some magical turnaround. Add a pathetic 1.5% sales growth over the last 5 years, low ROE (4.4%), and you’ve got a company that’s still alive only because it’s too old to die.
Introduction
Once a proud name in Kolkata’s pharma scene, Albert David is now a classic case of “legacy without glory.” The company makes everything from infusions to herbal dosage forms, yet sales have flatlined and profits collapsed. Recent quarters show a free fall in margins, with other income (₹28.6 crore) being the only thing saving the bottom line.
The Q1 FY26 results confirm fears: no new growth drivers, no product breakthroughs, just an expensive stock burning investors’ patience. P/E at 79 with negative margins? That’s like paying for a Ferrari and getting a bicycle.
Business Model (WTF Do They Even Do?)
Albert David manufactures:
- Pharma formulations – tablets,
